Thesis
DT120 ODT's Phase 3 MDD win sets up GAD readouts as the next binary — two pivotal trials will confirm or break the multi-indication thesis
DT120 ODT, an oral LSD formulation, has met its Phase 3 primary endpoint in MDD with an 8.1-point placebo-adjusted MADRS reduction, and is now in two fully enrolled Phase 3 trials in GAD. The thesis pivots on whether Voyage and Panorama replicate Phase 2b GAD efficacy, because positive results would support an NDA filing across two major indications simultaneously. Key regulatory risk is DEA scheduling of a psychedelic-class compound, and COMP360 failure in a related psychedelic depression indication could sharpen FDA scrutiny of the class.
Focus
Voyage Phase 3 topline readout - DT120 ODT in GAD
early Q3 2026
Bull
A positive Voyage readout would show a statistically significant and clinically meaningful reduction in HAM-A or analogous GAD endpoint at the primary timepoint, replicating the Phase 2b effect size (Cohen's d=0.81) and rapid onset observed in that study. This would confirm that DT120 ODT's efficacy generalizes beyond MDD, establish a two-for-two Phase 3 track record, and position the company for a potential NDA filing in GAD contingent on Panorama confirmation.
Bear
The most likely failure modes are a loss of the large Phase 2b effect size in a more heterogeneous pivotal population — GAD patients with comorbid anxiety-depression overlap can dilute signal — or insufficient durability of a single-dose regimen over the trial period. Enrollment at 214 participants in a 1:1 randomization provides moderate statistical power, meaning a smaller-than-expected true effect could yield a nominal miss even if directionally positive.
Unlock the full thesis for DFTX.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.